U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 12b-25



                                                COMMISSION FILE NUMBER 001-09974



                           NOTIFICATION OF LATE FILING



                                  (Check One):

[ ] Form 10-K & Form-10 KSB   [X] Form 11-K    [ ] Form 20-F
[ ] Form 10-Q & Form 10-QSB   [ ] Form N-SAR


For the Period Ended:  December 31, 2003


Nothing  in this  Form  shall be  construed  to imply  that the  Commission  has
verified any information contained herein.


If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates:




PART I- REGISTRANT INFORMATION

Full Name of Registrant: Enzo Biochem, Inc.
                         ------------------
Former Name if Applicable:
                           --------------------------------
Address of Principal Executive Office (Street and Number):60 Executive Boulevard
                                                          ----------------------
City, State and Zip Code: Farmingdale, New York 11735
                          ---------------------------


PART II - RULE 12b-25(b)AND (c)


If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check appropriate box.)

[X]    (a)    The reasons  described  in  reasonable  detail in Part III of this
              form  could  not be  eliminated  without  unreasonable  effort  or
              expense;

[X]    (b)    The subject annual report,  semi-annual report,  transition report
              on Form 10-K,  Form 20-F,  11-K or Form N-SAR,  or portion thereof
              will be filed on or before the 15th  calendar  day  following  the
              prescribed due date; or the subject quarterly report or transition
              report on Form 10-Q, or portion thereof will be filed on or before
              the fifth calendar day following the prescribed due date; and

[ ]    (c)    The  accountant's  statement  or other  exhibit  required  by Rule
              12b-25(c) has been attached if applicable.




PART III - NARRATIVE


State below in reasonable  detail the reasons why the Form 10-K and Form 10-KSB,
11-K,  20-F, 10-Q and Form 10-QSB,  N-SAR,  or the transition  report or portion
thereof could not be filed within the prescribed time period.


       THE  COMPANY'S  FORM 11-K FOR THE FISCAL  YEAR ENDED  DECEMBER  31,  2003
       CANNOT BE FILED WITHIN THE  PRESCRIBED  TIME PERIOD BECAUSE THE FINANCIAL
       INFORMATION  FOR THE YEAR ENDED  DECEMBER 31, 2003 COULD NOT BE COMPLETED
       BY THE  AUDITORS BY THE REQUIRED  FILING DUE DATE.  THE FORM 11-K WILL BE
       FILED AS SOON AS PRACTICABLE.





PART IV - OTHER INFORMATION



(1)    Name and  telephone  number  of  person  to  contact  in  regard  to this
       notification:


       Robert H. Cohen, (212) 801-6907
       -------------------------------
       (Name)(Area Code)(Telephone Number)

(2)    Have all other periodic reports required under Section 13 or 15(d) of the
       Securities  Exchange Act of 1934 or section 30 of the Investment  Company
       Act of 1940 during the



       preceding 12 months or for such shorter  period that the  registrant  was
       required to file such report(s) been filed? If the answer is no, identify
       report(s):

                                                               [X]  Yes  [ ]  No


(3)    Is it anticipated  that any  significant  change in results of operations
       from the corresponding  period for the last fiscal year will be reflected
       by the  earnings  statements  to be  included  in the  subject  report or
       portion thereof?

                                                               [ ]  Yes  [X]  No

       If so: attach an explanation of the anticipated  change, both narratively
       and  quantitatively,  and,  if  appropriate,  state  the  reasons  why  a
       reasonable estimate of the results cannot be made.


                               ENZO BIOCHEM, INC.
                               ------------------
                  (Name of Registrant as specified in charter)

       has  caused  this  notification  to  be  signed  on  its  behalf  by  the
       undersigned thereunto duly authorized.



Date:  June 28, 2004               By:      /s/ Barry W. Weiner
                                      -----------------------------------------
                                                Barry W. Weiner
                                                Chief Financial Officer